华仁药业：9月29日召开董事会会议

Group 1 - Huarun Pharmaceutical held a temporary board meeting on September 29, 2025, to discuss the election of a non-independent director [1] - For the first half of 2025, Huarun Pharmaceutical's revenue composition was 95.79% from pharmaceutical manufacturing and 4.21% from pharmaceutical commerce [1] - As of the report date, Huarun Pharmaceutical's market capitalization was 3.8 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yibao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [1]